ProQR Therapeutics (NASDAQ:PRQR) Given "Overweight" Rating at Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of ProQR Therapeutics (NASDAQ:PRQR - Free Report) in a research report report published on Friday morning,Benzinga reports. They currently have a $8.00 price target on the biopharmaceutical company's stock.

A number of other research analysts have also recently commented on the stock. Oppenheimer reduced their price target on shares of ProQR Therapeutics from $15.00 to $9.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 13th. JMP Securities reaffirmed a "market outperform" rating and set a $8.00 price objective on shares of ProQR Therapeutics in a research note on Friday. Evercore ISI assumed coverage on ProQR Therapeutics in a research note on Tuesday, April 29th. They issued an "outperform" rating and a $5.00 target price for the company. Chardan Capital restated a "buy" rating and set a $4.00 price target on shares of ProQR Therapeutics in a research report on Friday, March 14th. Finally, HC Wainwright boosted their price objective on ProQR Therapeutics from $10.00 to $12.00 and gave the company a "buy" rating in a research report on Friday, March 14th. One research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $8.00.

ProQR Therapeutics Price Performance

NASDAQ PRQR remained flat at $2.04 during trading hours on Friday. 408,452 shares of the company were exchanged, compared to its average volume of 654,349. The company has a market cap of $214.63 million, a PE ratio of -5.83 and a beta of 0.31. ProQR Therapeutics has a 1-year low of $1.07 and a 1-year high of $4.62. The firm has a 50-day simple moving average of $1.74 and a 200 day simple moving average of $1.96.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.02). ProQR Therapeutics had a negative return on equity of 53.49% and a negative net margin of 157.04%. The company had revenue of $4.89 million during the quarter, compared to the consensus estimate of $4.90 million. As a group, equities analysts predict that ProQR Therapeutics will post -0.31 EPS for the current year.

Hedge Funds Weigh In On ProQR Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. Jane Street Group LLC bought a new position in shares of ProQR Therapeutics in the 4th quarter worth approximately $30,000. Invesco Ltd. bought a new stake in shares of ProQR Therapeutics during the 4th quarter valued at $32,000. Alpine Global Management LLC purchased a new stake in shares of ProQR Therapeutics in the 4th quarter worth about $39,000. Two Sigma Securities LLC bought a new position in shares of ProQR Therapeutics in the 4th quarter worth about $40,000. Finally, ADAR1 Capital Management LLC bought a new position in ProQR Therapeutics during the 4th quarter valued at approximately $54,000. 32.65% of the stock is owned by institutional investors.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).